Syndax Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Syndax Pharmaceuticals, Inc. on May 18, 2016. The filing reports on corporate events related to clinical trial data presentations scheduled for the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical development updates and does not contain financial statements or quantitative financial data.
Material Changes
There are no material financial changes reported in this filing. The primary event is the announcement of upcoming clinical data presentations regarding the Company's drug candidates.
Outlook, Management Commentary, and Risks
- Clinical Data Presentation: The Company announced that clinical data from the National Cancer Institute's Cancer Therapy Evaluation Program will be presented at the ASCO meeting.
- ENCORE-601 Trial Results: Preliminary results from the ENCORE-601 Phase 1b/2, open-label trial are available as a published abstract. This trial evaluates entinostat in combination with Keytruda (pembrolizumab) for non-small cell lung cancer and melanoma patients.
- Reference Material: The full text of the press release is filed as Exhibit 99.1 and incorporated by reference.
Investor Verification Checklist
- Verify the full text of the press release filed as Exhibit 99.1 for detailed clinical data.
- Access the abstract at abstract.asco.org to review preliminary results for the ENCORE-601 trial.
- Monitor the 52nd Annual Meeting of the American Society of Clinical Oncology for the presentation of National Cancer Institute data.